Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — August 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #768

    Tak alle..En flaske vin knappes op her i Regstrup. Efter udmeldingen af min overtagelse af PI d. 31/7 har vi august 38% flere brugere, 42% nye brugere og 18% flere sidevisninger end samme periode sidste år. Stigningen i forhold til de seneste tre måneder er også markant. Måske et tilfælde. Jeg er dog en glad mand alligevel. 🙂

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #769

      Finanshus løfter kursmålet på Genmab med 26% til 2585. Børsen.

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #770

        Helge. Så må man håbe der følger lidt flere donationer med. ;-). God weekend til alle. 🙂

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #771

          This will not only be viewed as more convenient by some patients (but not all, note KOLs) but will be cheaper than using Ocrevus, Novartis argues. Whilst Roche’s product has a lower wholesale price of $65,000, Novartis says the total annual cost of Ocrevus rises on average to more than $100,000 when the price of infusions is taken into account.

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #772

            A more subtle difference between Kesimpta and Ocrevus is the former’s shorter half-life and association with faster B-cell repletion, note experts.

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #773

              KOLs are quick to acknowledge that Ocrevus is not frequently associated with complications that necessitate rapid B-cell repletion in patients, suggesting that at this is likely to be viewed as a ‘nice to have’ clinical benefit with Kesimpta rather than a meaningful advantage, even if there is some suggestion that B-cell depleting therapies may increase the risk of more severe COVID-19 infection

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #774

                Just a moment...

                favicon

                (www.firstwordpharma.com)

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  GeorgeBest
                  wrote on sidst redigeret af
                  #775

                  Det er Truist Securities (tidligere Sun Trust) der løfter kursmål til 2585 https://borsen.dk/nyheder/markedsberetninger/finanshus-saetter-genmab-kursmaal-op-med-en-fjerdedel

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #776

                    So they think infusion costs are $35,000??? For basically 2 infusions, admittedly long ones, but
                    that is nuts....

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #777

                      I know wonder what Dara IV estimated costs were, I mean, we knew Dara SC is a cost saver for hospitals, but this is a huge number $$

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #778

                        can't wait for January with a big raise in SC
                        prices 😄

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #779

                          🙂

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bibob
                            wrote on sidst redigeret af
                            #780

                            God søndag morgen. :-).

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bibob
                              wrote on sidst redigeret af
                              #781

                              Lidt om FDA godkendelsen af KdD i RRMM. https://www.onclive.com/view/fda-approves-daratumumab-plus-carfilzomib-dexamethasone-in-relapsed-refractory-myeloma?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #782

                                Godmorgen. 🙂

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #783

                                  bibob..Jeg håber det er lørdag. 🙂

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    bibob
                                    wrote on sidst redigeret af
                                    #784

                                    Selvfølgelig Helge. :-D. Det er ikke fordi jeg har en " bagskid " på. Bare en fejl 40. 😉

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      GeorgeBest
                                      wrote on sidst redigeret af
                                      #785

                                      Shares of Genmab A/S (NASDAQ:GMAB) reached a new 52-week high on Friday after HC Wainwright raised their price target on the stock from $40.00 to $41.00. HC Wainwright currently has a buy rating on the stock. Genmab A/S traded as high as $38.31 and last traded at $38.31, with a volume of 9217 shares traded. The stock had previously closed at $37.35.

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #786

                                        🙂

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #787

                                          GMAB 15:11 08/21/20 Genmab to hold a conference call CEO van de Winkel holds a company update conference call on August 26 -
                                          https://thefly.com/landingPageNews.php?id=3150049&headline=GMAB--Genmab-to-hold-a-conference-call- - I wonder who organised that 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger